Rectal Cancer Stage III Clinical Trial
Official title:
A Phase II Trial of Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer
This is a multicenter, single-arm, phase II study of nivolumab in combination with regorafenib in subjects with locally-advanced rectal cancer who are eligible for a curative treatment including pre-operative SCRT and TME(or watch & wait approach). The study is based on the Simon's two-stage design and a maximum of 60 subjects will be enrolled. In addition to the standard efficacy interim analysis according to the statistical design, a safety interim analysis will be performed on the first 6 subjects who have completed the study treatment to ensure safe continuation of the study investigation. Eligible subjects will be treated according to the following sequential treatment plan: - Induction treatment: This consists of treatment with nivolumab (240 mg intravenously, on day 1 and 15) and regorafenib (80 mg/day orally, from day 1 to 14) - Standard SCRT: This consists of 25 Gy delivered in 5 fractions (from day 22 to 26) - Consolidation treatment: This consists of treatment with nivolumab (240 mg intravenously, on day 29, 43 and 57) and regorafenib (80 mg/day orally, from day 29 to 49) - Surgery: Surgical resection will be performed according to the principles of TME (between day 74 and 87, i.e., between 7 to 8 weeks after completion of SCRT). As an alternative to surgery, subjects who achieve cCR can be offered a watch & wait approach. - Adjuvant chemotherapy: Administration of adjuvant chemotherapy will be left to the discretion of the treating physician The study also includes translational procedures (i.e. collection of tumour biopsies, blood samples and stool samples at pre-specified time points) for exploratory molecular and immune contexture analyses. These are mandatory for all study subjects.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05495308 -
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
|
||
| Recruiting |
NCT04598984 -
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
|
||
| Active, not recruiting |
NCT04246684 -
Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients
|
Phase 3 | |
| Completed |
NCT05723965 -
Using Artificial Intelligence to Predict Rectal Cancer Outcomes
|
||
| Not yet recruiting |
NCT05830890 -
Sentinel Lymph Node Biopsy in Rectal Cancer
|
N/A | |
| Completed |
NCT02363374 -
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer
|
Phase 2 | |
| Recruiting |
NCT03561142 -
Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy.
|
Phase 2 | |
| Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05148767 -
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
|
Phase 4 | |
| Recruiting |
NCT06254521 -
The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer
|
Phase 2 | |
| Completed |
NCT01325649 -
Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma
|
N/A | |
| Recruiting |
NCT04970498 -
Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
|
||
| Active, not recruiting |
NCT03840239 -
TNT to Increase the Clinical Complete Response Rate for Distal LARC
|
Phase 2 | |
| Active, not recruiting |
NCT03391843 -
Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer
|
Phase 2 |